Trial
NCT02176122
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.
Phase IVTERMINATEDSAFETYConfidence: MEDIUM
Sponsor
The University of Queensland
Collaborators
International Society of Chemotherapy; Australian Society for Antimicrobials; Queensland Clinical Trials & Biostatistics Centre; Australasian Society for Infectious Diseases
Condition
Bloodstream Infections
Intervention
Meropenem
Why stopped
Secondary to third interim analysis by the study DSMB.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-27